These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20178396)

  • 1. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward.
    Khalili H; Dashti-Khavidaki S; Hossein Talasaz AH; Tabeefar H; Hendoiee N
    J Manag Care Pharm; 2010 Mar; 16(2):114-21. PubMed ID: 20178396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of acid suppressive therapy in hospitalized non-critically ill patients.
    Sheikh-Taha M; Alaeddine S; Nassif J
    World J Gastrointest Pharmacol Ther; 2012 Dec; 3(6):93-6. PubMed ID: 23494814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of A Collaborative Strategy to Reduce the Inappropriate Use of Acid Suppressive Therapy in Non-Intensive Care Unit Patients.
    Belfield KD; Kuyumjian AG; Teran R; Amadi M; Blatt M; Bicking K
    Ann Pharmacother; 2017 Jul; 51(7):577-583. PubMed ID: 28622739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication reconciliation effect on prolonged inpatient stress ulcer prophylaxis.
    Zeigler AJ; McAllen KJ; Slot MG; Barletta JF
    Ann Pharmacother; 2008 Jul; 42(7):940-6. PubMed ID: 18577762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stress ulcer prophylaxis in hospitalized patients not in intensive care units.
    Grube RR; May DB
    Am J Health Syst Pharm; 2007 Jul; 64(13):1396-400. PubMed ID: 17592004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the use and cost of stress ulcer prophylaxis for surgical inpatients.
    Wijaya D; Padolo E; Ardianto C; ; Matulatan F; Alderman CP;
    J Basic Clin Physiol Pharmacol; 2020 Jan; 30(6):. PubMed ID: 31926087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of clinical pharmacy services on stress ulcer prophylaxis prescribing and related cost in patients with renal insufficiency.
    Mousavi M; Dashti-Khavidaki S; Khalili H; Farshchi A; Gatmiri M
    Int J Pharm Pract; 2013 Aug; 21(4):263-9. PubMed ID: 23418812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is deep vein thrombosis prophylaxis appropriate in the medical wards? A clinical pharmacists' intervention study.
    Khalili H; Dashti-Khavidaki S; Talasaz AH; Mahmoudi L; Eslami K; Tabeefar H
    Pharm World Sci; 2010 Oct; 32(5):594-600. PubMed ID: 20623385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variables associated with stress ulcer prophylaxis misuse: a retrospective analysis.
    Issa IA; Soubra O; Nakkash H; Soubra L
    Dig Dis Sci; 2012 Oct; 57(10):2633-41. PubMed ID: 22427129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An interprofessional approach to reducing the overutilization of stress ulcer prophylaxis in adult medical and surgical intensive care units.
    Tasaka CL; Burg C; VanOsdol SJ; Bekeart L; Anglemyer A; Tsourounis C; Rennke S
    Ann Pharmacother; 2014 Apr; 48(4):462-9. PubMed ID: 24473490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inappropriate continuation of stress ulcer prophylaxis beyond the intensive care setting.
    Farley KJ; Barned KL; Crozier TM
    Crit Care Resusc; 2013 Jun; 15(2):147-51. PubMed ID: 23961576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to stress-related mucosal damage prophylaxis guideline in patients admitted to the Intensive Care Unit.
    Rafinazari N; Abbasi S; Farsaei S; Mansourian M; Adibi P
    J Res Pharm Pract; 2016; 5(3):186-92. PubMed ID: 27512710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current practice of stress ulcer prophylaxis in a surgical patient cohort in a German university hospital.
    Rauch J; Patrzyk M; Heidecke CD; Schulze T
    Langenbecks Arch Surg; 2021 Dec; 406(8):2849-2859. PubMed ID: 34518899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients.
    Heidelbaugh JJ; Inadomi JM
    Am J Gastroenterol; 2006 Oct; 101(10):2200-5. PubMed ID: 16952283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pharmacy intervention on the use of proton-pump inhibitors in the hospital setting.
    Atkins R; Smith L
    Consult Pharm; 2013 Dec; 28(12):786-92. PubMed ID: 24322962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of stress ulcer prophylaxis drug regimentation in surgical patients.
    Wijaya D; Suharjono ; Matulatan F; Padolo E
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):645-649. PubMed ID: 34214378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variables Associated with Adherence to Stress Ulcer Prophylaxis in Patients Admitted to the General Hospital Wards: A Prospective Study.
    Farsaei S; Ghorbani S; Adibi P
    Adv Pharm Bull; 2017 Apr; 7(1):73-80. PubMed ID: 28507939
    [No Abstract]   [Full Text] [Related]  

  • 19. Overuse of Acid-Suppression Therapy at an Urban Tertiary Hospital.
    Redfern RE; Brown M; Karhoff KL; Middleton JL
    South Med J; 2015 Dec; 108(12):732-8. PubMed ID: 26630894
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.